Cancer genetics
Precision answers for inherited and tumour-related cancer risk
Our cancer genetics portfolio spans hereditary risk assessment, targeted familial variant confirmation, and tumour-level molecular profiling. Each test matched precisely to your clinical question
Who this is for
Tests for every clinical context
Cancer genetics is not one-size-fits-all. Our tests serve different patients, different clinical questions, and different points in the cancer pathway.
Patients and at-risk individuals
If cancer runs in your family, targeted genetic testing can tell you whether you've inherited the same risk before disease develops. Early answers enable early action.
Oncologists and clinicians
Tumour profiling and panel-based testing support treatment selection, confirm hereditary diagnoses, and guide surveillance decisions for patients and their families.
8%
of all cancers are caused by inherited genetic mutations
36
genes covered in our breast/colon hereditary cancer panel
78
variants analysed by the Oncomine Precision Assay across 50 key genes
Our tests
Choose by clinical need
Each test below is matched to a specific clinical scenario. Select a test to explore its full scope, sample requirements, and report detail.
Hereditary risk for patients and families
Patient-facing
Familial mutation
Confirms the presence or absence of a specific cancer-predisposing variant already identified in your family. The most targeted and cost-effective starting point for at-risk relatives.
- Blood or saliva
- Index report required
Patient-facing
BrCA panel - BrCA1 & BrCA2
Screens the two most clinically significant genes in hereditary breast cancer. Informs treatment planning, surgical decisions, and cascade testing within families.
- Blood or saliva
- 2 genes
Patient & clinician
BrCo panel - breast & colorectal
A broader 36-gene panel covering hereditary breast, colorectal, ovarian, and prostate cancers. Includes MMR and HRR gene coverage for patients with complex or multi-cancer family histories.
- Blood or tumour
- 36 genes
Clinician-ordered
Custom cancer panel
A gene panel configured to the specific requirements of an oncologist or oncology practice. Ideal when a standard panel doesn’t match the clinical question.
- Blood or tumour
- Fully customisable
Tumour profiling - for clinicians and oncologists
Clinician-ordered
Oncomine Precision Assay (OPA)
An NGS-based tumour profiling assay detecting 78 variants – including mutations, copy number variants, and fusions – across 50 key oncogenes. Supports treatment selection across solid tumour types.
- FFPE or liquid biopsy
- 78 variants, 50 genes
Clinician-ordered
Oncomine Myeloid Assay (OMA)
A targeted NGS panel for haematological malignancies. Identifies somatic variants relevant to myeloid cancers including AML, MDS, and MPN to guide diagnosis and treatment decisions.
- Blood or bone marrow
- Myeloid-specific
Clinician-ordered
DPYD testing
Pre-treatment screening for DPYD variants that cause severe, potentially fatal toxicity to fluoropyrimidine chemotherapy (5-FU, capecitabine). A critical safety test before initiating treatment.
- Blood
- Pre-treatment safety
What sets us apart
Your clinician receives a direct geneticist briefing with every result.
Every result is reviewed and interpreted by a qualified Genetix geneticist in direct consultation with the treating clinician. Your doctor receives a full clinical briefing before results are communicated to you, ensuring every finding is contextualised within your personal medical history and care plan.
For all cancer genetics, pharmacogenomics, and whole genome tests, patient reports are released only if authorised by the referring clinician. Your doctor is your primary point of contact for results and next steps.
